References
- 1. Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med. 2003;3:147-182. doi: 10.1055/s-2003-40673.10.1055/s-2003-4067315199478
- 2. Balasubramaniyam N, Kolte D, Palaniswamy C, et al. Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura. Am J Med. 2013;126:1016.e1-7. doi: 10.1016/j.amjmed.2013.03.021.10.1016/j.amjmed.2013.03.02123993262
- 3. Gandhi K, Aronow WS, Desai H, et al. Cardiovascular Manifestations in Patients With Thrombotic Thrombocytopenic Purpura: A Single-center Experience. Clin Cardiol. 2010 Apr;33(4):213-6. doi: 10.1002/clc.20731.10.1002/clc.20731665300020394041
- 4. Wahla AS, Ruiz J, Noureddine N, Upadhya B, Sane DC, Owen J. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol. 2008;81:311-316. doi: 10.1111/j.1600-0609.2008.01112.x.10.1111/j.1600-0609.2008.01112.x18616514
- 5. Frutcher O, Blich M, Jacob G. Fatal acute myocardial infarction during severe thrombocytopenic purpura. Am J Med Sci. 2002;323:279-280.10.1097/00000441-200205000-0001012018673
- 6. Torbey E, Yacoub H, McCord D, Lafferty J. Two Cases and Review of the Literature: Primary Percutaneous Angiography and Antiplatelet Management in Patients with Immune Thrombocytopenic Purpura. ISRN Hematology. 2013;2013:174659. doi: 10.1155/2013/174659.10.1155/2013/174659388867924459590
- 7. Russo A, Cannizzo M, Ghetti G, Branzi A. Idiopathic thrombocytopenic purpura and coronary artery disease: comparison between coronary artery bypass grafting and percutaneous coronary intervention. Interact Cardiovasc Thorac Surg. 2011;13:153-157. doi: 10.1510/icvts.2011.271296.10.1510/icvts.2011.27129621576275
- 8. Fujino S, Niwa S, Fujioka K, et al. Primary Percutaneous Coronary Intervention by a Stentless Technique for Acute Myocardial Infarction with Idiopathic Thrombocytopenic Purpura: A Case Report and Review of the Literature. Intern Med. 2016;55:147-152. doi: 10.2169/internalmedicine.55.4544.10.2169/internalmedicine.55.454426781014
- 9. Shen F, Nfor T, Bajwa T. Recurrent acute myocardial infarction in patients with immune thrombocytopenic purpura. J Patient Cent Res Rev. 2014;1:41-45. doi: 10.17294/2330-0698.1010.10.17294/2330-0698.1010
- 10. Sakai H, Goto S, Kim JY, et al. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost. 2000;84:204-209.10.1055/s-0037-1613997
- 11. Sonneveld MA, Cheng JM, Oemrawsingh RM, et al. Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Thromb Haemost. 2015;113:577-584. doi: 10.1160/TH14-07-0589.10.1160/TH14-07-058925472874
- 12. Lim MY, Pruthi RK. Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: a single center experience and review of the literature. Thromb Res. 2012;130:316-322. doi: 10.1016/j.thromres.2012.02.050.10.1016/j.thromres.2012.02.05022445429
- 13. Rathore S, Deleon D, Akram H, Sane D, Ball T. Percutaneous Coronary Intervention and the Management of Acute Coronary Syndromes in Patients With von Willebrand Disease. J Invasive Cardiol. 2013;25:E81-E86.
- 14. Rana MA, Vutukuri NM, Acharya MM, Akkus NI. Acute coronary syndrome and coronary intervention in a patient with type 2M von Willebrand disease. Int J Cardiol. 2014;176:484-485. doi: 10.1016/j.ijcard.2014.06.066.10.1016/j.ijcard.2014.06.06625127978
- 15. Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood. 2016;128:178-184. doi: 10.1182/blood-2015-12-635094.10.1182/blood-2015-12-635094494619927106121
- 16. Zawilska K, Podolak-Dawidziak M. Therapeutic problems in elderly patients with hemophilia. Pol Arch Med Wewn. 2012;122:567-576.10.20452/pamw.1466
- 17. Staritz P, de Moerloose P, Schutgens R, Dolan G; ADVANCE Working Group. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia. Haemophilia. 2013;19:833-840. doi: 10.1111/hae.12189.10.1111/hae.1218923710576
- 18. Fefer P, Gannot S, Lubetsky A. Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome: an interventional dilemma: case series, review of the literature, and tips for management. J Thromb Thrombolysis. 2013;35:271-278. doi: 10.1007/s11239-012-0802-y.10.1007/s11239-012-0802-y22956409
- 19. Minuk L, Jackson S, Iorio A. Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study). Haemophilia. 2015;21:736-741. doi: 10.1111/hae.12768.10.1111/hae.1276826222883
- 20. Fransen van de Putte, Fischer K, Pulles AE, et al. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res. 2012;130:157-162. doi: 10.1016/j.thromres.2011.12.012.10.1016/j.thromres.2011.12.01222209337
- 21. Fogarty PF, Mancuso ME, Kasthuri R, et al. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015;21:589-597. doi: 10.1111/hae.12652.10.1111/hae.1265225689278
- 22. Provan D, Baglin T, Dokal I. Oxford Handbook of Clinical Haematology. 4th ed. Oxford University Press; 2015. p. 258-261.10.1093/med/9780199683307.001.0001
- 23. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. N Engl J Med. 2004;350:114-124. doi: 10.1056/NEJMoa03557210.1056/NEJMoa03557214711910
- 24. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176-2184. doi: 10.1182/blood-2013-03-460154.10.1182/blood-2013-03-46015423823316
- 25. Tortorella G, Calzolari M, Tieghi A, Muià N, Piccin A, Gugliotta L. Acute coronary syndrome (ACS) in patients with essential thrombocytemia (ET). What is the best treatment. International Journal of Cardiology 2016;203:225–227. http://dx.doi.org/10.1016/j.ijcard.2015.10.043.10.1016/j.ijcard.2015.10.04326512843
- 26. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372-380. doi: 10.3324/haematol.12053.10.3324/haematol.1205318268279
- 27. Ziakas PD. Effect of JAK2 V617F On Thrombotic Risk In Patients With Essential Thrombocytemia: Measuring the Uncertain. Haematologica. 2008;93:1412-1414. doi: 10.3324/haematol.12970.10.3324/haematol.1297018641024
- 28. Lee HS, Park LC, Lee EM, et al. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin Lymphoma Myeloma Leuk. 2012;12:70-75. doi: 10.1016/j.clml.2011.10.002.10.1016/j.clml.2011.10.00222088920
- 29. Pósfai É, Marton I, Borbényi Z, Nemes A. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. Anatol J Cardiol. 2016;16:397-402. doi: 10.14744/AnatolJCardiol.2015.6125.10.14744/AnatolJCardiol.2015.6125533137027182615
- 30. Zhang Y, Zheng K, Zheng M, Liu Q, Meng L. The positive therapeutic effect in a patient of Evans syndrome combined with acute myocardial infarction. Int J Clin Exp Med. 2015;8:9590-9594.
- 31. Kizilirmak F, Demir GG, Cakal B, Bekoz HS, Olgun FE. Evans syndrome with non-ST segment elevation myocardial infarction complicated by hemopericardium. Indian Heart J. 2016;68(Suppl2):S280-S283. doi: 10.1016/j.ihj.2015.11.041.10.1016/j.ihj.2015.11.041506745427751316
- 32. Zöller B, Li X, Sundquist J, Sundquist K. Risk of Subsequent Coronary Heart Disease in Patients Hospitalized for Immune-Mediated Diseases: A Nationwide Follow-Up Study from Sweden. PLoS One. 2012;7:e33442. doi: 10.1371/journal.pone.0033442.10.1371/journal.pone.0033442330639722438933
- 33. Assanasen C, Quinton RA, Buchanan GR. Acute myocardial infarction in sickle cell anemia. J Pediatr Hematol Oncol. 2003;25:978-981.10.1097/00043426-200312000-0001514663284
- 34. Gladwin MT, Sachdev V. Cardiovascular Abnormalities in Sickle Cell Disease. J Am Coll Cardiol. 2012;59:1123-1133. doi: 10.1016/j.jacc.2011.10.900.10.1016/j.jacc.2011.10.900388118822440212
- 35. Bhaskar V, Joshi C. Effect of Sickle Cell Disease on Cardiovascular System: A 4.5 Years Autopsy Study Conducted in a Tertiary Care Center of Central India. International Journal of Scientific Study 2016;4:188-192. doi: 10.17354/ijss/2016/404.
- 36. van Bijnen STA, van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria J Thromb Haemost. 2012;10:1-10. doi: 10.1111/j.1538-7836.2011.04562.x.10.1111/j.1538-7836.2011.04562.x22077430
- 37. Muñoz-Linares C, Ojeda E, Forés R, et al. Paroxysmal nocturnal hemoglobinuria: a single Spanish center’s experience over the last 40 year. Eur J Haematol. 2014;93:309-319. doi: 10.1111/ejh.12346.10.1111/ejh.12346423287824758317
- 38. Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007;5:642-645. doi: 10.1111/j.1538-7836.2007.02379.x.10.1111/j.1538-7836.2007.02379.x17319910
- 39. Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016;103:649-654. doi: 10.1007/s12185-016-1995-1.10.1007/s12185-016-1995-127059871
- 40. Shin HS, Kang TS. A Case of Late Stent Thrombosis Following Platelet Transfusion in a Patient With Aplastic Anemia. Korean Circ J. 2012;42:54–57. doi: 10.4070/kcj.2012.42.1.54.10.4070/kcj.2012.42.1.54328375622363385
- 41. Altwegg SC, Altwegg LA, Maier W. Intracoronary thrombus with tissue factor expression heralding acute promyelocytic leukaemia. Eur Heart J. 2007;28:2731. doi: 10.1093/eurheartj/ehm216.10.1093/eurheartj/ehm21617561495
- 42. Sargsyan Z, Higgins C, Alexandrescu S, Ott DA, Jain SK. Acute Promyelocytic Leukemia as a Cause of Intracoronary Drug-Eluting-Stent Thrombosis. Tex Heart Inst J. 2012;39:416-419.
- 43. Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016;128:488-496. doi: 10.1182/blood-2016-01-635060.10.1182/blood-2016-01-635060552453227235136
- 44. Cahill TJ, Chowdhury O, Myerson SG, et al. Myocardial Infarction With Intracardiac Thrombosis as the Presentation of Acute Promyelocytic Leukemia. Circulation. 2011;123:e370-e372. doi: 10.1161/CIRCULATIONAHA.110.986208.10.1161/CIRCULATIONAHA.110.98620821403118
- 45. Muñiz AE. Myocardial infarction and stroke as the presenting symptoms of acute myeloid leukemia. J Emerg Med. 2012;42:651-654. doi: 10.1016/j.jemermed.2009.04.061.10.1016/j.jemermed.2009.04.06119500934
- 46. Colović N, Bogdanović A, Virijević M, Vidović A, Tomin D. Acute Myocardial Infarction during Induction Chemotherapy for Acute MLL t(4;11) Leukemia with Lineage Switch and Extreme Leukocytosis. Srp Arh Celok Lek. 2015;143:734-738.10.2298/SARH1512734C26946771
- 47. Cohen Y, Amir G, Da’as N, Gillis S, Rund D, Polliack A. Acute Myocardial Infarction as the Presenting Symptom of Acute Myeloblastic Leukemia With Extreme Hyperleukocytosis. Am J Hematol. 2002;71:47-49. doi: 10.1002/ajh.10155.10.1002/ajh.1015512221675
- 48. Oshima T, Ikutomi M, Shinohara H, et al. Acute Myocardial Infarction Caused by Thrombotic Microangiopathy Complicated With Myelodysplastic Syndrome. International Heart Journal. 2016;5:634-636. http://doi.org/10.1536/ihj.16-100.10.1536/ihj.16-10027628419
- 49. Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. American Journal of Blood Research. 2011;1:160-166.
- 50. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte Count and Coronary Heart Disease. Implications for Risk Assessment. J Am Coll Cardiol. 2004;44:1945-1956. doi: 10.1016/j.jacc.2004.07.056.10.1016/j.jacc.2004.07.05615542275
- 51. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol. 2005;25:658-670. doi: 10.1161/01.ATV.0000156877.94472.a5.10.1161/01.ATV.0000156877.94472.a515662026
- 52. Assiri AH, Lambda M, Veinot JP. Chronic lymphocytic leukemia involving the coronary arteries with accompanying acute myocardial infarction. Cardiovasc Pathol. 2005;14:324-326. doi: 10.1016/j.carpath.2005.07.006.10.1016/j.carpath.2005.07.00616286042
- 53. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study. J Natl Cancer Inst. 2007;99:206-214. doi: 10.1093/jnci/djk029.10.1093/jnci/djk02917284715
- 54. Galper SL, Yu JB, Mauch PM, et. al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117:412-418. doi: 10.1182/blood-2010-06-291328.10.1182/blood-2010-06-29132820858859
- 55. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-1886. doi: 10.1182/blood-2006-07-034405.10.1182/blood-2006-07-03440517119114
- 56. Roy A, Khanna N, Senguttuvan NB. Rituximab-vincristine chemotherapy-induced acute anterior wall myocardial infarction with cardiogenic shock. Tex Heart Inst J. 2014;41:80-82. doi: 10.14503/THIJ-12-2853.10.14503/THIJ-12-2853396749024512409
- 57. Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15:187-190.
- 58. Gogia A, Khurana S, Paramanik R. Acute Myocardial Infarction after First Dose of Rituximab Infusion. Turkish Journal of Hematology. 2014;31:95-96. doi:10.4274/Tjh.2013.0247.10.4274/Tjh.2013.0247399662724764738
- 59. Rathi S, Shakir F, Sech C, Lazzara R. Non-Hodgkin Lymphoma Causing Acute Myocardial Infarction and Tachyarrhythmia Am J Cardiol. 2009;104:450-452. doi: 10.1016/j.amjcard.2009.03.065.10.1016/j.amjcard.2009.03.06519616683
- 60. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991-4998. doi: 10.1182/blood-2009-11-252072.10.1182/blood-2009-11-252072289015020299513
- 61. Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010;116:22-26. doi: 10.1182/blood-2009-12-257519.10.1182/blood-2009-12-25751920339094
- 62. Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:437-444. doi: 10.1182/asheducation-2010.1.437.10.1182/asheducation-2010.1.43721239832
- 63. Weijuan L, Frank C, Daniel L, et al. Cardiovascular Complications of Novel Multiple Myeloma Treatments. Circulation. 2016;133:908-912. https://doi.org/10.1161/CIRCULATIONAHA.115.018351.10.1161/CIRCULATIONAHA.115.01835126927008
- 64. Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol. 2010;91:903-906. doi: 10.1007/s12185-010-0586-9.10.1007/s12185-010-0586-920458563